Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 199, Tung Hwa North Road, Taipei 105, Taiwan.
Clin Liver Dis. 2013 Aug;17(3):413-23. doi: 10.1016/j.cld.2013.05.005. Epub 2013 Jun 21.
Chronic hepatitis B virus (HBV) infection is a dynamic state of interactions between HBV, the hepatocytes, and the patient's immune system. HBV replication is the key driving force for the HBV-related immune clearance events that determine the outcomes. The extended immune clearance phase is associated with liver disease progression, including development of cirrhosis and hepatocellular carcinoma (HCC). Thus, the primary aim of therapy is to eliminate or permanently suppress HBV to reduce hepatitis activity and thereby reduce the risk or slow the progression of liver disease.
慢性乙型肝炎病毒（HBV）感染是 HBV、肝细胞和患者免疫系统之间相互作用的动态状态。HBV 复制是决定结果的 HBV 相关免疫清除事件的关键驱动力。延长的免疫清除期与肝病进展相关，包括肝硬化和肝细胞癌（HCC）的发展。因此，治疗的主要目的是消除或永久抑制 HBV，以降低肝炎活动度，从而降低或减缓肝病的进展。
